BMS’s Anti-LAG3 Drug Could Offer Safer Combo Partner To Opdivo Monotherapy Patients
Company Unveils Phase II/III Relatlimab Combo Data At ASCO
Executive Summary
Data show better safety than Opdivo/Yervoy, though what appears to be slightly lower efficacy, in first-line metastatic or unresectable melanoma.
You may also be interested in...
Bristol’s Growth Plan Faces First Test In 2022
Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.
Broader Horizons For Advanced Biotech In 2022: New Targets, Settings For IO, Cell And Gene Therapy
US FDA’s user fee goal calendar for 2022 already contains 45 applications for novel agents featuring a wide array of biologics, from cell therapy in cancer and hematology to bispecifics and new immuno-oncology targets that could move the field beyond PD-1/L1.
BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics
Bristol executives reiterated the company’s aggressive revenue growth expectations while outlining the impact Revlimid generics will have in Europe, Japan and – to a limited extent – in the US.